PCore Diabetes Flashcards

0
Q

Who to screen for diabetes and prediabetes

A

ppl age 45 and above
esp if bmi >= 25 (obese)*

may not be true for all ethnic groups PCOS (polycystic ovarian syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Diabetes fasting glucose

A

126 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Screening people < 45 if one or more additional risk factor

A
  • habitually physically inactive
  • part of high risk ethnic group (african americans, latino, Native American, asian american, Pacific Islander)
  • had baby weighing > 9 pounds or dx with gestational diabetes mellitus
  • had impaired fasting glucose or impaired glucose tolerance on previous testing
  • other clinical conditions assoc w insulin resistance acanthosis nigricans
  • family hx (1st degree relative)
  • PCOS
  • HDL < 35 mg/dL or triglycerides > 250 mg/dL
  • hx of vascular dz
  • hypertensive (>= 140/90)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diagnosing diabetes based on Hg A1c

A

dx can be made based on elevated value
–> comparable in screening utility to fasting glucose and 2-hr 75 g glucose tolerance testing

a1c >= 6.5% : diagnostic for diabetes; test result must be repeated on subsequent day to rule out lab error, unless dx is evident on clinical grounds (hyperglycemia crisis for ex)

a1c 5.7-6.4% : diagnostic for pre-diabetes; test must also be repeated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pros and cons of using A1c to dx diabetes

A

pros: convenience over fasting glucose testing and 2 hr oral glucose tolerance test; no need to fast; less subject to daily fluctuations during periods of stress or illness;
cons: cost, limited availability in certain parts of world, race and age variability, inability to use in pts w certain anemias and hemoglobinopathies (eg sickle cell dz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fasting plasma glucose to dx diabetes

A
  • children and non pregnant adults
    pros: easier to admin, acceptable to pts, costs less than oral glucose tolerance test
    fasting: no calorie intake for >= 8 hrs

diabetes: fgp >= 126 mg/dL dx pts with diabetes!
pre-diabetes: >= 100 and < 126 ; impaired fasting glucose = elevated fasting plasma glucose

dx of prediabetes or diabetes must be repeated and confirmed on sepearate day unless sx of diabetes present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Oral glucose tolerance test (OGTT)

A

75 g oral glucose tolerance test more sensitive, slightly more specific than FPG
cons: poorly reproducible, more $$$, inconvenient for patients, rarely used in clinical practice

diabetes: plasma glucose >= 200 mg/dL drawn 2 hrs post OGTT
pre-diabetes: *impaired glucose tolerance >= 140 and < 200 mg/dL) after 75 g oral glucose load on ogtt in presence of fpg concentration < 126 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Random / casual plasma glucose dx diabetes

+

A

any time of day regardless of last meal

if > 200 mg/dL + classic symptoms of diabetes (polyuria, polydipsia, unexplained weight loss) makes dx and does not need to be repeated on subsequent day!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Confirming dx with multiple screening tests in same person

A
  • use same screening test in same person for confirmation
  • if two diff screening tests used in same pt: if both tests reach diagnostic threshold, then dx can be confirmed at that time (even if both are initial screens)
  • if 2 tests discordant, the test that is above threshold should be repeated and dx made based on confirmed test
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Criteria to test children for t2dm

initiate age 10 yrs or at onset of puberty (if puberty occurs at younger age);
repeat every 2 yrs
test used: fasting plasma glucose

A

overweight (bmi > 85th percentile for age and sex; weight for height > 85th percentile, or weight > 120 % of ideal for height)

+

any 2 of following risk factors:

  • fam hx t2dm in 1st or 2nd degree relative
  • race/ethnicity (Native American, african american, latino, asian american, Pacific Islander)
  • signs of insulin resistance or conditions associated w insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, or PCOS)
  • maternal hx diabetes or gdm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When to screen women postpartum with gdm

A

6 wks - 12 wks postpartum

should be followed up with subsequent screening for devt of diabetes or pre-diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Preventing diabetes progression in ppl at high risk or those with pre-diabetes

A

insulin secretion may be adequeate to maintain fasting blood glucose levels < 126 mg/dL but process of insulin resistance already present

modest weight loss and increasing phyiscal activity can reduce risk of diabetes by 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Patients with IFG and IGT prediabetes and any of the following…

A
< 60 yrs age
bmi >= 35 kg/m2
fam hx diabetes in 1st deg relative
elevated triglycerides, reduced hdl
htn
a1c > 6%

in addition to lifestyle modification: metformin (850 mg 2x/day)
no other meds recommended for this group yet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Prevention in pts with IFG or IGT prediabetes (ADA recommendations) and no other significant risks or categorizations (in another slide)

A
  1. lifestyle modification (5-10% weight loss and moderate intensity physical activity about 30 min/day)
    2.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Followup in pts with ifg/igt being treated with metformin

A

a1c: semi annually in ppl with ifg/igt being treated with metformin

assess and treat for other cardiovascular risk factors (hyperlipidemia, htn, tobacco use)

counsel for lifestyle modification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

follow up pts with ifg/igt not being treated with metformin

A

a1c: annually screen

assess and treat for other cardiovascular risk factors: hyperlipidemia, htn, tobacco use)

counsel for lifestyle modification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Signs and symtpoms undiagnosed diabetes

A

most are asymptomatic!!!!

undiagnosed gluocse intolerance and perisistent hyperglycemia can eventually –> classic polydipsia, polyuria, fatigue, weight loss, blurry vision

other signs: obesity, evidence of metabolic syndrome or cardiovascular dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Assess risk factors for atherosclerosis

A

smoking, htn, obesity, dyslipidemia, fam hx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Laboratory evaluation patients with diabetes risk or diabetes

A

a1c
fasting lipid profile: total cholesterol, hdl, triglycerides, LDL
microalbuminuria in t1dm pts who had diabetes for >= 5 yrs and in all patients with t2dm (some advocate testing pubertal children sooner than 5 yrs of diabetes)
serum creatinine in adults (children if proteinuria present)
TSH in all t1dm; t2dm if indicated
ekg in adults if clinically indicated
urinalysis for ketones, protein, sediment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

REcommendations to diabetic patients in managing brief illnesses (viral syndromes)

A
  • continue taking medications
  • check sugars more frequently (every 2-4 hrs)
  • check ketones (every 4 hrs)
  • drink lots of non-caffeinated fluids

call dr if cant hold down fluids or carb intake for > 6 hrs, cant eat regular food for one day, develop intractable heavy vomiting or diarrhea, drowsiness or recurrent hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Complications in diabetes: Hypoglycemia

symptoms and plan

A

causes: taking too much diabetes medicine, missing a meal or snack, exercising too much, drinking alcohol
signs: feeling weak or dizzy; nervous, shaky, or confused; irritability; sweating more; noticing sudden changes in heartbeat; feeling very hungry; losing consciousness; develop seizures

plan: test blood glucose; if <= 70 mg/dL, eat one of the following right away:
2-3 glucose tablets; 1/2 cup (4 oz) any fruit juice, 1/2 cup regular non diet soft drink; 1 cup milk; 5-6 pieces hard candy; 1-2 teaspoons of sugar or honey

check blood glucose again 15 minutes after glucose intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Complications in diabetes: hyperglycemia

symptoms

A

causes: forgetting to take medicine on time, eating too much and getting too little exercise; being ill can also raise blood glucose levels
symptoms: frequent hunger; frequent thirst; frequent urination; blurred vision; fatigue; weight loss; poor wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Risk factors for depression in diabetic patients include

A

age >65; previous hx depression; unmarried; female; poor physical health; poor mental health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Diabetes self-mgmt education programs (dsme)

A

diabetes care; skill based; pt centered; longitudinal

better outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When to test glucose if pt is NOT on insulin if pt has new dx of diabetes, recent therapy adjustment, or glucose level outside of target

A

3x/day:

  • before breakfast
  • before main meal of day
  • 2 hrs after start of main meal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

When to test glucose if pt is NOT on insulin and glucose in target range

A

3x/day every 3rd day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

When to test glucose if ON insulin

–> taking basal and bolus (meal-associated) insulin

A

test 4x/day:

  • before breakfast
  • mid-morning
  • mid to late afternoon
  • mid evening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

When to test glucose if ON insulin

–> taking basal insulin only

A

test fasting glucose daily and perform other pre and post meal tests intermittently

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

In all diabetic pts takiing or not taking insulin, test:

A
  1. whenever suspecting hypoglycemia
  2. before driving if having trouble sensing hypoglycemia

dont forget to reassess self-monitored blood glucose skills periodically (esp if glucometer #s dont correspond to hga1c levels)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Hemoglobin A1c

A

patients average glycemic levels over past 2-3 months

without diabetes: 4-6% (4-6% of a non diabetic persons hemoglobin has nonenzymatically attached glucose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

HOw often to check A1c

A

patients whose therapy has changed recently: quarterly
patients not meeting glycemic control: quarterly
patients at glycemic control: 2x/yr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Effects of Lowering A1c levels in diabetes…

A

reduce neuropathic and microvascular complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

ADA recommendations to target goals for A1c and self-monitored blood glucose levels

A

hga1c for diabetic patients: < 180 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Glycemic target goals american assoc clin endocrinologists

A

hgba1c: < 6.5%
premeal glucose < 110
postmeal glucose 140 mg/dL (2 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Glycemic target goals international diabetes center

A

Hgba1c < 7%
premeal glucose 70-140
postmeal glucose <160 mg/dL (2 hrs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Glycemic target goals american diabetes association

A

Hgba1c < 7%
premeal glucose 90-130 mg/dL
postmeal glucose < 180 mg/dL (1-2 hrs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Medical nutrition therapy with registered nutritionist

A

can reduce a1c in newly diagnosed t2dm by 2% and by 1% with t2dm for 4 or more years

overall goals:

  • prevent and manage chronic complications
  • improve gneeral overall health thru food choices and physical activity
  • achieve and maintain optimal metabolic outcomes
  • address individual needs

focus: wt mgmt, carb counting, reduced dietary fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Weight mgmt

A

strong link bw obese or overweight status and diabetes

obesity: independent risk factor for hyperlipidemia, htn, and cardiovascular dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

ADA recommendations of weight mgmt

A
  • decrease in 500-1000 kcal/day will allow slow progressive wt loss of 1-2 lbs/week
  • wt loss diets should supply 1000-1200 kcal/day for women and 1200-1600 kcal/day for men
  • drug therapy for obesity may be appropriate to reduce wt in selected patients but lifestyle modifications still important
  • severely obese pts: gastric bypass or gastroplasty may be appropriate alternative and can –> reduce doses or discontinuation of diabetes meds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Carb counting possible benefits

A

limit hyperglycemia
improve weight loss
reduce insulin resistance
prevent complications of diabetes

15 carbs = 1 carb “choice”
c””

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

International diabetes center recommended food plan

A

women
weight loss: 2-3 choices/meal
maintain wt: 3-4 choices/meal
for v active person: 4-5 choices/meal

men
weight loss: 3-4 choices/meal
maintain wt: 4-5 choices/meal
v active person: 4-6 choices/meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Low carb diets not recommended for diabetic patients!

A

restricting carbs <130 grams/day may be below brain, nervous system, and other metabolic requirements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Dietary fat

A

total fat :
25-35% of total calories
saturated and tras fatty acids = principal dietary factors of LDL cholesterol (a major factor in cardiovascular dz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Alcohol

A

not recommended but those who drink:

women: 1 or less/day
men: 2 or less/day

drink = 12 oz beer, 5 oz wine, 1.5 oz distilled spirits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

PHysical activity benefits

A

reduce risk of cardiovascular dz, reduce insulin resistance, assist in wt reduction, assist in wt mgmt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Aerobic activity

A

moderate intensity: achieve 50-70% maximum heartrate

vigorous aerobic exercise: > 70% max heartrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Exercise recommendations

A

moderate intensity: >= 150 min/wk distributed over 3 days w no more than 2 days consecutively w out activity

vigorous intensity: >= 90 mins/wk over 3 days w no more than 2 consecutive days w out activity

47
Q

Resistance activity

A

recommended! at least 3x/wk unless contraindication

resistance training improves insulin sensitivity just as well as aerobic activity

48
Q

Cardiac stress testing before exercise

A

patients whose 10 yr risk of coronary event is >= 10%

stress test with EKG considered prior to beginning aerobic activity exceeding demands of everyday living

49
Q

Exercise in presence of long term complications of diabetes

A

diabetic patients with retinopathy, peripheral neuropathy, autonomic dysfunction may need more individualized exercise recs

50
Q

Metformin overview

A

increases insulin sensitivity more than sulfonylureas or insulin

(lower levels of insulin ahcieve same level of glycemic control)

less likely to see weight changes

51
Q

7 classes of oral agents for diabetes

A

Secretagogues:

  1. 1st generation sulfonylureas
  2. 2nd generation sulfonylureas
  3. meglitinide
  4. d-phenylalanine

Insulin sensitizers:

  1. biguianides
  2. thiazolidinediones
  3. alphaglucosidase inhibitor:
52
Q

Secretagogues

A

allow pancreas beta cells to secrete insulin in response to glucose challenge
–> useful in patients with insulin deficiency

common side effects: hypoglycemia, weight gain, mild gastrointestinal complaints, rarely skin rxns, photosensitivity, and cholestatic hepatitis

most secretagogues contraindicated in pregnancy!
used with caution in pts with liver dz and renal dz (except repaglinide and nateglinide which dont have renal dosage reqs)

secretagogues: 1st and 2nd gen sulfonylureas, meglitinides, and d-phenylalanine derivatives

53
Q

First and Second generation sulfonylureas

A

sulfonylureas bind to sulfonylureas receptors on beta cells which stimulate insulin secretion or sensitize beta cells to presence of glucose

2nd gen: more commonly prescribed than 1st gen; fewer side effects than 1st gen
a1c can decrease as much as 2.3% w sulfonylureas

most patients: begin w low dose of sulfonylurea and increase them at 1-2 wks intervals depending on self monitored glucose readings and a1c results
once daily preps available

as t2dm progresses, beta cells secrete less insulin and thus sulfonylureas will not be able to optimize glucose levels by themselves;

most clinicians dont d/c but add insulin sensitizers

54
Q

Meglitinides

repaglinide

A
rapid acting, short duration insulin secretagogues
repaglinide is only approved drug in class in US

as effective as a sulfonylurea
take before each meal and with any bedtime snacks

pro: allows patients flexibility to skip a dose if meal is skipped (prevents hypoglycemia)
con: pt must take several times a day for effectiveness

not contraindicated in renal insufficiency

55
Q

D-phenylalanine derivatives

nateglinide

A

faster acting and shorter duration than meglitinides (rapaglinide)

nateglinide is only member
can be used in patients with renal insufficiency

pro: useful in patients found to have optimal fasting glucose levels but high post-prandial glucose levels
con: take several times a day

56
Q

INsulin sensitizers in non-diabetics

A

possible use for delaying t2dm in pts with insulin resistance, glucose intolerance (pre-diabetes), or have high risk for diabetes

used in pts with PCOS (carries component of insulin resistance)

57
Q

Biguanides
metformin
INsulin sensitizers

A

decrease gluconeogenesis from liver
increases glucose uptake into muscle tissues
enhances basal metabolic rate
may lower food intake bc of its gastrointestinal side effects

do not: stimulate insulin secretion from pancreas

exact mxn of action not well understood

indications: pts with insulin resistance; good consideration in those with cholesterol issues

only metformin in US
can reduce a1c by 2% and fasting glucose levels by 60 mg/dL
can decrease or stabilize patient weight, can reduce cholesterol and triglyceride levels, and may reduce myocardial infarction risk

metformin should be started slow and low
500 mg dose start (at dinner) ; additional dose can be added to breakfast after 1 wk
(higher dose tablets and extended release tablets available)

  • data shows most clinically effective dose: 2000 mg/day*
    caution: those with liver dz, active pulmonary or cardiac dz; contraindicated in men with cr > 1.5 mg/dL or women with cr > 1.4 mg/dL ; withold prior to any radiology study requiring contrast dye or if going to surgery; restore once renal function normal

Metformin is category B drug (no evidence of risk in humans) in pregnancy and breastfeeding

Metformin side effects: flatulence, diarrhea, nausea, metallic taste

58
Q

Thiazolidinediones

rosiglitazone, pioglitazone

A

indicated for pts with insulin resistance

insulin sensitizing effect on peroxisome proliferator-activated nuclear receptors in liver cells, adipose tissue, muscle

side effects: mild anemia, weight gain, mild edema due to volume expansion

can be used in pts with renal insufficiency; liver function monitoring recommended periodically while using these drugs;

contraindicated in people with liver disease who have ALT > 2.5 times upper limit of normal; contraindicated in pregnancy; may stimulate ovulation in insulin-resistant anovulatory women

thiazolidinediones contraindicated in pts with class III or IV New YOrk Heart Association functional status

reduction of insulin resistance also reduces blood glucose levels

59
Q

Specifically rosiglitazone risks (controversy)

further details

A

assoc with significant increase in risk of myocardial infarction and w increase in risk of death from cardiovascular causes in 1 study

contradictory evidence in other studies…

pts taking rosiglitazone esp known to have underlying heart disease or at high risk of heart attack should talk to pcp about this

60
Q

Carbohydrate absorption delay agents

alpha glucosidase inhibitors

A

delay disaccharide and complex carbohydrate absorption in small intestine and allow it to occur instead in large intestine and colon

–> allows improvement of glucose control; does not have same effect on lactose

excellent for: pts w high 2 hr post meal hyperglycemia; can be used in ppl w both insulin resistance and deficiency

must be used w each meal to be effective

effects: reduce a1c by .5-1% when combined w other oral agents or insulin
2 alpha glucosidase drugs in US: acarbose and miglitol

side effects: diarrhea, flatulence
start low and slow to prevent these side efx

may cause reversible liver enzyme elevation (alpha glucosidease )

contraindicated in: pts with liver dz, inflammatory bowel dz

pros: do not cause hypoglycemia by themselves but if hypoglycemia develops in conjunction with sulfonylureas or insulin, pt may use milk to correct glucose levels

61
Q

First line therapy acc to ADA

A

metformin** (most endocrinologists prefer)
thiazolidinediones,
secretagogues (if problem is more pancreatic dysfunction than insulin resistance)

62
Q

Monotherapy vs. Combination therapy for t2dm

A

50% of pts require a second agent after 3 yrs of monotherapy

1 insulin sensitizer + secretagogue
or
2 insulin sensitizers

consider combo therapy sooner if: pts has a1c>9% before monotherapy has been instituted or a1c>8% after monotherapy tried

triple therapy becoming more common: consider whether these pts actually need insulin instead

63
Q

Normal: basal and post prandial insulin

A

basal: pancreas constantly secretes basal levels of insulin comprising 50% of bodys requirement
bolus: remaining 50% after meals

(about 50% of t2 diabetics require insulin to keep their a1c < 7%)

64
Q

Types of insulin:
bolus
rapid acting

A

covers meals

ex: lispro, aspart

lispro (humalog): onset 15 mins, peak 30-90 mins, duration 3-5 hrs
aspart (novolog): onset 15 mins, peak 40-50, duration 3-5 hrs

65
Q

Types of insulin:
bolus insulin
short acting

A

regular insulin
covers meals

onset 30-60 mins, peak 50-120, duration 5-8 hrs

66
Q

types of insulin
basal insulin
intermediate acting

A

background

NPH, lente

67
Q

types of insulin
basal insulin
extended intermediate acting

A

ultralente
background insulin

onset 4-8 hrs, peak 8-12, duration 36

68
Q

types of insulin
premixed
intermediate acting + short acting

A

NPH/regular

69
Q

types of insulin
premixed
intermediate acting + rapid acting

A

NPH/lispro

70
Q

Bolus insulin

A

covers a meal

either rapid or short acting

71
Q

rapid acting bolus insulin

A

take within 15mins before meal
cleared from body in 3-5 hrs
monitor glucose 2 hrs post meal to make adjustment in dose

allows for: flexibility; pts can exercise at any time
postprandial glucose levels: tend to be lower in rapid acting than with short acting insulin

good choice for: ppl who dont snack throughout day,

72
Q

short acting bolus insulin

A

better for pts who frequently delay eating after an injection or eat throughout the day

onset of action: 30 -60 mins
cleared from body in 5-8 hrs

73
Q

basal insulin

intermediate acting

A

covers baseline insulin needs of body
intermediate acting: NPH, lente
short duration of action
act quickly

NPH: onset 1-3 hrs, peak 8 hrs, duration 20 hrs
or : onset 1-2.5 hrs, peak 7-15 hrs, duration 18-24 hrs

74
Q

types of insulin
basal insulin
long acting

A

glargine
background insulin

onset 1 hr, peak none, duration 24 hrs

75
Q

basal insulin

extended intermediate acting

A

ultralente

acts somewhat longer than nph thus extended intermediate acting

76
Q

types of insulin
basal insulin
long acting

A
glargine (brand name lantus)
long acting insulin analogue
formulated for delayed absorption over 24 hours w no peak levels
can be administered once a day
lower risk of hypoglycemia

cannot be mixed in same syringe w other insulin types!
usually used in conjunction w bolus insulin

77
Q

types of insulin

intermediate and short acting mixtures

A

onset, peak, and duration of action reflect composite of intermediate (NPH) and short (regular) or rapid (lispro, aspart) acting components
but ONE peak of action

78
Q

INsulin regimens: basic insulin regimens

A

candidates: use for pts with 2 or more of following:

consistent schedule, regular mealtimes, < 10hours bw breakfast and dinner, not prepared to take multiple injections, unable to mix or measure insulin

79
Q

rapid acting + NPH

basic insulin regimen

A

use for pts who choose not to snack; consider when post meal hyperglycemis is present

AM: rapid acting + NPH
PM: rapid acting
bedtime: NPH

80
Q

rapid acting + NPH premix pen

basic insulin regimen

A

use premixed pen as easier way to start insulin or if unable to measure/mix: use for pts who choose not to snack; consider when post meal hyperglycemia is present

AM: rapid actig, NPH (pen)
PM: rapid acting, nph (pen)
bedtime: nothing

81
Q

nph + regular

basic insulin regimen

A

use for pts who choose to snack; may be cheaper than rapid acting + nph

am: regular, nph
pm: regular
bedtime: nph

82
Q

nph + regular premix pen

basic insulin regimens

A

use premixed pen as easier way to start insulin or if unable to measure/mix; use for pts who choose to snack; may be cheaper than rapid acting + nph

am: regular, nph (pen)
pm: regular, nph (pen)
bedtime: nothing

83
Q

nph with oral agents

basic insulin regimens

A

nph with oral agents

use for type 2 dm w high fasting glucose w or w out subsequent elevated pre meal glucose; continuing biguianides or thiazolidinediones to add glycemic control

am: oral agents
pm: oral agents
bedtime: nph

84
Q

Glargine with oral agents

basic insulin regimens

A

use for type 2 dm w high fasting glucose (w or w out subsequent elevated pre meal glucose); continue biguanides or thiazolidinedions to add glycemic control

am: oral agents
pm: oral agents
bedtime: glargine

85
Q

Dosing of premixed insulin w nph and rapid acting component

A

more expensive but provides better post meal glucose control

usual starting dose: .3-.5 u/kg/day then –> .7-1.2 u/kg/day

86
Q

Dose of single nighttime glargine

A

initial dose: .1-.2 u/kg/day
recommended by manufacturer: initial dose of 10
target: morning fasting glucose of < 140 mg/dL

dose can be increased by 2-5 units every 4-7 days until morning fasting glucose has reached target

87
Q

Basic vs advanced insulin regimens

A

basic: easier for new pts but inflexible and can increase risk of hypoglycemia

advanced: more flexible for pts life demands (exercise regimen, work schedules, meal intake variability)
- -> requires both increased freq of insulin admin and self monitored glucose levels

most advanced regimens: rapid acting insulin + long acting insulin

88
Q

rapid acting + nph or ultralente

advanced insulin regimens

A

am: ra+nph or ultralente
noon: ra only
pm: ra+nph or ultralente
bedtime: small dose of nph for some ppl

89
Q

rapid acting + glargine

advanced insulin regimens

A

am: ra
noon: ra
pm: ra
bedtime: glargine

90
Q

Insulin dosage for advanced insulin therapy

A

initial: .4-.5 u/kg/day for pt naive to insulin, moves up to 1-2 u/kg/day

typically half of total goes to bolus dose and half to basal dose

91
Q

Adjusting insulin dosage

A

always adjust for hypoglycemia first!

if all self monitored glucose levels > 200 mg/dL, then total daily dose of insulin should be increased by .1 u/kg/day

fasting and premeal glucose levels will help adjust basal insulin doses;
2 hr post meal glucose levels help adjust bolus insulin doses:

if current dose is < 10 u: dose can be increased by 1 u if glucose levels high or lowered by 1 u if glucose levels low

if current dose is > 10 u, dose can be increased by 10% if glucose levels high or lowered by 10% if glucose levels low

92
Q

Target glucose levels for rapid acting insulin

A

achieved when 2 hr post meal glucose level is within 20-40 mg of pre meal glucose level

93
Q

Side effects of injected insulin

A

lipodystrophy: at sites of injection,
- lipohypertrophy more often in men
- lipoatrophy more often in women

*changing injection sites can prevent this side effect

systemic rxns (rare): allergies can develop, varying from urticaria to anaphylaxis
more common in patients with penicillin allergies or atopic dermatitis
also occurs more frequently in pts using insulin intermittently

densensitization therapy now available

94
Q

New agents: incretin mimetic agents

A

incretins = GI hormones
ex: glucagon like peptide 1
released during food intake –> promotes insulin secretion and suppression of glucagon from pancreas

exanetide: 1st drug in this class (incretin mimetic agents)
- improves glucose control by mimicking effects of glucagon like peptide 1 (natural mammalian incretin hormone)

use to treat t2dm in conjunction w metformin and/or sulfonylurea

recommended dosage: 5 mug to 10 mug 2x/day subcutaneously before breakfast and dinner

in RCT: exenatide improved glycemic control and promoted wt loss up to 2.8 kg

most common adverse effects: nausea, vom, diarrhea, dose dependent hypoglycemia

pts should be closely monitored for hypoglycemia, esp when exenatide added to sulfonylurea therapy

good option for: pts who fail to get glycemic control while on maximum dose metformin and/or sulfonylureas

alternative therapy for: pts who cant tolerate other antidiabetic drugs

95
Q

Dipeptidyl peptidase-4 inhibitors

new medications

A

dpp-4 is enzyme that normally breaks down and inactivates incretins

hypoglycemic drug!
by inhibiting breakdown of incretins, insulin secretion and glucagon suppression are both enhanced

as blood glucose levels normalize, amts of insulin released and glucagon suppressed diminishes

dpp4 inhibitors less suspectible to severe hypoglycemic episodes than other hypoglycemic meds

sitagliptin: first drug to be released in this class

intended for: ppl w t2dm, contraindicated in ppl w t1dm or in a state of “diabetic ketoacidosis”

must be used w caution in ppl w renal impairment

other drugs in this class pending approval

96
Q

cardiovascular disease

Prevention and Management of diabetic complications: cardiovascular disease

A

major cause of mortality in diabetic patients : cardiovascular disease
major cause of morbidity, direct, and indirect costs

t2dm: independent risk factor for macrovascular disease
common coexisting conditions of t2dm (metabolic syndrome) are also risk factors for macrovascular disease

signs and sx of cvd imp to recognize

97
Q

Hypertension

prevention and mgmt of diabetes complications

A

screening and dx: bp taken on diabetic pts at every clinic visit
pts with systolic pressure >= 130 or diastolic bp >= 80 should have bp checked on a diff day to confirm dx of prehtn or htn

goals: bp in diabetics; lower than gen pop
sbp=140 or dbp>=90) : drug therapy + lifestyle modifications (medical nutrition therapy and physical exercise)
2. diabetic patients with pre htn (sbp 130-139 or dbp 80-89) : 3 months lifestyle modifications; if not goal bp then RAAS blocker initiated (ARB, ACEi)
3. all diabetics wtih htn: regimen including ACEi or ARB bc of demonstrated renal protection; additional meds can be added if bp not optimized: diuretics, beta blockers, calciumchannel blockers)
–> most pts w htn need >1 med to optimize bp
4. in t2dm pts with htn and microalbuminuria, ACEi and ARBs delay nephropathy; in t2dm pts w htn and macroalbuminuria, ARBs shown to delay nephropathy; ACEi and ARBs contraindicated in pregnancy!
5. orthostatic bp measurements taken in pts w diabetes and htn to assess for autonomic dysfunction

98
Q

Hyperlipidemia

prevention and mgmt diabetic complications

A

screening: higher prevalence of dyslipidemia in pts with t2dm; in adult diabetes screening for lipid disorder recommended annually or more often (to achieve goals)
–> pts with low risk lipid values (LDL50, triglycerides40y: statin initiated to reduce LDL by 30-40% regardless of pts LDL baseline
if =40 and women to HDL >=50
(fibrates may be good option says module; this may change)

combo therapies not shown to decrease cvd at this time but may be needed

99
Q

Antiplatelet agents

prevention and mgmt diabetes complications

A

use aspiring thereapy (75-162 mg/day) as primary prevention strategy in t2dm pts at increased cvd risk, including: ppl >40y or who have additional risk factors (fam hx cvd, htn, smoking, dyslipidemia, albuminuria)

consider aspirin therapy in ppl bw 30-40 yrs, esp in presence of other cv risk factors; ppl s syndrome)

combo therapy using other antiplatelet agents (clopidogrel) in addition to aspirin should be used in pts w severe and progressive cvd

other antiplatelet agents may be reasonable alternative for high risk pts with aspirin allergy, bleeding tendency, receiving anti coagulant therapy, recent GI bleed, and clinically active hepatic dz (who are not candidates for aspirin therapy)

100
Q

Smoking cessation

A

all patients! adivse not to smoke, discuss smoke cessation and treatment

101
Q

Coronary heart disease screening and treatment

A

recommendations from ADA:

pts >55y: w or w out htn, but w another cv risk factor (hx of cvd, dyslipidemia, microalbuminuria, or smoking), ACEi (if not contraindicated) should be considered (reduce risk of cv events)

pts w prior MI or pts undergoing major sx: beta blockers + ACEi considered to reduce mortality

asymptomatic pts: consider risk factor eval to stratify by 10yr risk and treat risk factors

–> pts w decompensated or acute CHF: metformin use contraindicated!
thiazolidinediones assoc w fluid retention; use can be complicated by devt of chf
caution in prescribing tzds in setting of known chf or other heart dz + pts w preexisting edema or concurrent insulin therapy required

102
Q

Nephropathy screening and treatment

prevention and mgmt complications

A

goals: reduce risk and slow progress of nephropathy; optimize glucose control and bp control
- -> in ppl with any degree of chronic kidney dz, protein intake should be reduced : daily allowance .8g/kg

screening: all t2dm pts should be screened yearly for urine microalbumin (start at dx)
serum cr: measure annually to estimate GFR in all pts w diabetes (regardless of microalbuminuria)
–> dont use serum cr alone to measure renal function but use it to measure GFR and stage true renal function or dysfunction

103
Q

Treatment in diabetes (htn and renal)

A

t2dm:
-pts with htn and microalbuminuria: ACEi and ARB shown to delay progression to macroalbuminuria
- pts with htn and macroalbuminuria: ARBs shown to delay nephropathy
–>ACEi and ARB contraindicated in pregnancy
ADA: recommend continued surveillance of urine microalbumin/protein to assess therapy response and renal dz progression

presence of nephropathy: initiate protein restriction to dihydropyridine-sensitive calcium channel blockers not effective as initial therapy to slow progression of nephropathy and should only be used as adjunct to ACEi or ARB to lower bp

if ACEi, ARB, or diuretics used: check serum K levels (K will be high with ACEi and ARB and aldosterone inhibitors/K sparing; K will be low with loop and thiazide diuretics)

consider referral to renal specialists when GFR falls <60 mL/min or if mgmt of htn or hyperkalemia becomes hard

104
Q

DM and CKD

A

DM may not be cause of CKD in diabetic pt

specific cause of CKD should be investigated fully

term of “diabetic glomerulopathy” should be reserved for biopsy-proven kidney dz caused by diabetes

105
Q

Retinopathy screening and treatment

prevention and mgmt complications of diabetes

A

general: glycemic control can reduce risk an dprogression of diabetic retinopathy; optimal bp control can also reduce risk; aspirin plays no role in preventing or exacerbating diabetic retinopathy!!!

106
Q

Diabetic retinopathy screening

A

comprehensive optho soon after dx made
repeat annual exams
screening less often if eye exam normal or more often if retinopathy found
Presence of retinopathy related to duration of diabetes

women with diabetes who become pregnant: full eye exam in 1st trimester, frequent repeat evals throughout; doesnt apply to women who develop gestational diabetes (bc these ppl not at increased risk for diabetic retinopathy)

see pics for proliferative vs non-proliferative retinopathy

107
Q

Laser photocoagulation for diabetic retinopathy

A

effective at slowing progression of retinopathy and reducing visual loss but trtmt usually doesnt restore lost vision

108
Q

Neuropathy screening and treatment

prevention of complications and mgmt

A

1) diabetic peripheral neuropathy: all pts should be screened for distal symmetric polyneuropathy at dx and at least annually

dpn screening test: pinprick sensation, temperature, vibration perception, ankle reflex testing
128 hz tuning fork, reflex hammer, 10-g monofilament test
(>2 of these tests should occur annually)

– > once dx of dpn established need specialized foot care to prevent risk of amputation ; inspect insensitive feet every 3-6 months, pts should be taught foot care

symptomatic treatment of dpn: start with optimize gluocse control (avoid extremes)
dpn pain manifestations can be managed with tricyclic drugs, gabapentin, 5-hydroxytryptamine, and norepinephrine reuptake inhibitors

2) diabetic autonomic neuropathy
major clinical manifestations: resting tachycardia, exercise intolerance, orthostatic hypotension, constipation, gastroparesis, erectile dysfunction, impaired neurovascular function, hypoglycemic autonomic failure, “brittle diabetes”

assessment of autonomic dysfunction should occur at initial diagnosis of t2dm

treatment of diabetic autonomic neuropathy: metoclopramide for gastroparesis; bladder and erectile dysfunction medications

109
Q

ASsessing foot complications

A

refer patients who smoke or w prior lower extremity complications to foot care specialists for ongoing preventive care and life long surveillance

initial screen for peripheral artery dz should include hx for claudication and assessment of pedal pulses
(ankle brachial index may be helpful bc many pts with pad are asymptomatic)

–> amputation and foot ulceration = most common consequences of diabetic neuropathy and major causes of morbidity and disability in ppl with diabetes

increased risk of ulcers or amputations: ppl who had diabetes >10 yrs, male, poor glucose control, or have cv, retinal, or renal complications

110
Q

Foot related risk conditions assoc w inc risk of foot amputation

A

increased risk of ulcers or amputations: ppl who had diabetes >10 yrs, male, poor glucose control, or have cv, retinal, or renal complications

conditions assoc:
peripheral neuropathy with loss of protective sensation, altered biomechanics (in presence of neuropathy), evidence of increased pressure (erythema, hemorrhage under a callus), bony deformity, peripheral vascular dz (dec or absent pedal pulses), hx of ulcers or amputation, severe nail pathology

111
Q

Immunizations in diabetic patients

A

preventable: influenza (vaccinate all diabetic ppl >6months old), pneumonia (one lifetime vaccine for pneumococcus then again when age >64 yrs previously immunized if vaccine administered 5 years prior;
(both assoc w high morbidity and mortality) in elderly ppl with chronic dzs

112
Q

Continuous quality improvement (CQI)

A
  • concept origianted from world of buisiness and manufacturing
  • undelying principle: always room for improvement
  • ocnstantly improve operations, processes, activities to meet requirements in efficient, consistent , cost effective manner
  • focus is not on individuals but on processes
  • CQI promotes need for objective data to analyze and improve processes; also applicable in heatlh care settings
  • effective cqi projects found to directly improve health outcomes
  • ADA considers ongoing cqi vital to delivering quality diabetes care
113
Q

Improving diabetes care: alarming statistics

A
  • 37% of diagnosed diabetes have a1c <=200
  • only 7.3% diagnosed diabetes have all 3 parameters at target goal

largest obstacles to optimal care: fragmented health care delivery system that lacks clnical info capabilities, often duplicates services, not designed for delivering chronic health care

  • interdisciplinary team approaches that collaborate w patients in self-empowerment and self-mgmt education have been found to be better suited for pts w chronic care issues
  • continuous quality improvement: institute of medicine recommends changes to delivery systems so they provide care that is evidence based, patient centered, systems oriented, includes info technolgy
114
Q

Continuous Quality Improvement (formal list: core concepts)

A

CORE CONCEPTS:

  • quality is defined as meeting and/or exceeding expectations of customers (patients, families, communities); patients and families can participate at the practice level
  • success achieved through meeting needs of those we serve
  • most problems found in processes, not ppl; CQI doesnt seek to blame but rather to improve processes
  • unintended variation in processes can lead to unwanted variation in outcomes, there fore we seek to reduce or eliminate unwanted variation
  • its possible to achieve continual improvement through small, incremental changes using scientific method
  • continuous improvement is most effective when it becomes natural part of way everyday work is done and not a peripheral periodic activity
115
Q

Continuous Quality Improvement (formal list: core steps in continuous improvement)

A

CORE STEPS IN CONTINUOUS IMPROVEMENT

  • define problem before trying to solve it
  • understand process before attempt to control it
  • identify which problems are priorities before attempting to correct everything
  • no such thing as failure bc can learn from all processes
  • form a team that has knowledge of system needing improvement
  • understand needs of ppl who are served by system
  • idenitfy and define measures of success
  • brainstorm potential change strategies for producing improvemet
  • plan, collect, use data for facilitating effective decision making
  • apply scientific method to test and refine changes
116
Q

Screening for diabetes

A

in patients 45+ (esp if bmi >= 25): if normal, test again in 3 years) if no other risk factors
–> expert opinion